Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Operating Leases (2019 - 2025)

C4 Therapeutics' Operating Leases history spans 7 years, with the latest figure at $53.6 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 10.61% year-over-year to $53.6 million; the TTM value through Dec 2025 reached $53.6 million, down 10.61%, while the annual FY2025 figure was $53.6 million, 10.61% down from the prior year.
  • Operating Leases reached $53.6 million in Q4 2025 per CCCC's latest filing, down from $55.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $75.2 million in Q2 2022 to a low of $10.9 million in Q3 2021.
  • Average Operating Leases over 5 years is $55.1 million, with a median of $62.2 million recorded in 2024.
  • Peak YoY movement for Operating Leases: skyrocketed 569.59% in 2022, then dropped 10.61% in 2025.
  • A 5-year view of Operating Leases shows it stood at $30.8 million in 2021, then surged by 130.59% to $71.0 million in 2022, then dropped by 7.35% to $65.8 million in 2023, then dropped by 8.78% to $60.0 million in 2024, then dropped by 10.61% to $53.6 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Operating Leases are $53.6 million (Q4 2025), $55.2 million (Q3 2025), and $56.9 million (Q2 2025).